Evaluation of the Benefit of Ropeginterferon Treatment in Patients with Polycythemia Vera
Results: Twenty-three patients (15 men and 8 women) with a median age of 57 years were enrolled, with 87.5% having the JAK617F mutation. Six patients had a history of thrombosis. Besremi was used as a first-line treatment in 11 patients and as a second-line treatment in 12 patients after Hydroxyurea...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Romanian Society of Hematology
2025-03-01
|
| Серія: | Documenta Haematologica |
| Предмети: | |
| Онлайн доступ: | https://www.dhrrh.ro/wp-content/uploads/2025/03/DHRRH-2025-1-art5.pdf |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|